Physician profile
Mohan Patel
NPI 1538152863
$8,064.10
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,520 · 2020: $1,661 · 2021: $2,393 · 2022: $2,113 · 2023: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $376.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,749.79 | 2019-2023 | Saxenda, Wegovy |
| Glaxosmithkline, LLC. | $799.18 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.94 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $602.05 | 2019-2023 | Farxiga |
| Pfizer INC. | $545.67 | 2019-2022 | |
| Amgen INC. | $439.59 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $403.96 | 2019-2022 | |
| Amarin Pharma, INC. | $397.15 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $356.92 | 2019-2022 | |
| Lilly USA, LLC | $324.36 | 2019-2023 | Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $257.79 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.16 | 2019-2023 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $185.34 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $178.70 | 2020-2022 | |
| Astellas Pharma US INC | $157.53 | 2022-2023 | Myrbetriq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $141.43 | 2019-2023 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $94.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.62 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $54.85 | 2020-2022 | |
| Esperion Therapeutics, INC. | $52.95 | 2020-2021 | |
| Abbvie INC. | $46.70 | 2022-2023 | |
| Dexcom, INC. | $43.40 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $40.78 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $38.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.57 | 2022 | |
| Grifols USA, LLC | $15.62 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.01 | 2022 | |
| Cequr Corporation | $12.70 | 2022 | |
| Horizon Therapeutics Plc | $11.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.67 | 2020 | |
| Hikma Pharmaceuticals USA | $11.36 | 2019 | |
| Tactile Systems Technology INC | $11.28 | 2019 | |
| Allergan, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.